The PennZone

PITTSBURGH, Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J. Coury, Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same date to review the quarterly results and provide an update on the company's February 28 Investor Event.

More on The PennZone

• Flamingo Compliance Launches Schengen Area Trip Planning Tools as New Digital Border Controls Take Effect
• HHS Announces Major Push to Address Psychiatric Drug Risks: CCHR Applauds Focus on Informed Consent and Safe Tapering
• PhaseZero Launches Eight AI Agents for Manufacturers and Distributors - Connecting Sales, Support, and Operations Teams Across Full Commerce Journey
• @tickerbitcoinbb and @girl_still_cute Announce the Arrival of SPROTO AEON BABY 1.0 – A New Chapter for the HarryPotterObamaSonic10Inu Universe
• Michigan Fitness Foundation Gifts EPEC Moves K–5 PE Curriculum Program to Educators during Michigan Moves Month

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.225.9448 or 203.518.9708 for international callers (Conference ID: VTRSQ322).  A replay of the webcast also will be available on the website.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

More on The PennZone

• Sidow Sobrino, the One and Only World's No.1 Superstar®, Launches Dangerous Joy
• Modern Site Builders Launches WolfResume.com, an AI Career Kit Built for ATS Hiring
• Slotozilla Expands Bonus Portfolio and Affiliate Reach Following iGB Barcelona 2026
• ThoroughCare Expands Remote Patient Monitoring with Withings Integration
• Wellsboro Earns Gold Bird Town Certification, Highlighting Conservation Leadership

SOURCE Viatris Inc.

---

Show All News | Disclaimer | Report Violation